Finch Therapeutics Group Inc Stock price
Is Finch Therapeutics Group Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,127 stocks worldwide.
Key metrics
Finch Therapeutics Group Inc Stock Analysis
Analyst Opinions
7 Analysts have issued a Finch Therapeutics Group Inc forecast:
Analyst Opinions
7 Analysts have issued a Finch Therapeutics Group Inc forecast:
Don't miss a Thing! We will send you all news about Finch Therapeutics Group Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Company Profile
Finch Therapeutics Group, Inc. engages in the development of microbiome drugs. Its platform includes Human-First Discovery that enables reverse translation from clinical data to engineer the composition of the microbiome based on disease-modifying mechanisms. The company was founded by Mark Smith, Andrew Noh, Tom Borody and Zain Kassam in September 2017 and is headquartered in Somerville, MA.
| Head office | United States |
| CEO | Mr. Blischak |
| Employees | 1 |
| Founded | 2014 |
| Website | finchtherapeutics.com |


